Page 6 - Pharma Industry
Pharma GCCs tap artificial intelligence to fast-track drug discovery
They are not just cutting down drug development time, but also the cost involved in it. AI is reshaping how drugs and therapies are developed
 "Pharma GCCs tap artificial intelligence to fast-track drug discovery")
Lupin carves out consumer healthcare biz into wholly owned subsidiary
The carve-out will be effective from 1 July 2025, according to the company's regulatory filing on the exchanges.
 "Lupin carves out consumer healthcare biz into wholly owned subsidiary")
KKR's JB Chemicals exit cements its strong healthcare track record
The sale of its 46.39 per cent stake in JB Chemicals to Torrent Pharmaceuticals comes over four years after KKR acquired control of the company in 2020
 "KKR's JB Chemicals exit cements its strong healthcare track record")
Biological E to make HPV9 vaccine under licensing pact with Recbio
BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in UNICEF and PAHO tenders
 "Biological E to make HPV9 vaccine under licensing pact with Recbio")
Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore
India's top drugmakers are reportedly sitting on their highest cash reserves in at least five years, up over 120% from FY20
 "Pharma majors turn to acquisitions as cash stockpile hits ₹49,000 crore")
Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate
Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK
 "Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate")
NPPA fixes retail prices for 41 drug combinations, including empagliflozin
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments, citing steep price drops and growing generic availability
 "NPPA fixes retail prices for 41 drug combinations, including empagliflozin")
Zydus signs deal with Agenus for BOT and BAL cancer therapies in India
Zydus Lifesciences has partnered with Agenus to license the cancer immunotherapies Botensilimab and Balstilimab for India and Sri Lanka, expanding its oncology offerings
 "Zydus signs deal with Agenus for BOT and BAL cancer therapies in India")
Sun Pharma halts development of SCD-044 drug after trial disappointment
Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis
 "Sun Pharma halts development of SCD-044 drug after trial disappointment")
Medical representatives barred from govt hospitals to stop pharma influence
The Centre's move seeks to curb the influence of pharmaceutical companies. Sharing of information must now happen through email or other digital platforms
 "Medical representatives barred from govt hospitals to stop pharma influence")
Lupin signs licensing deal with SteinCares for ranibizumab in LatAm
Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina
Sun Pharma to invest $25 million in Pharmazz Inc; raises stake to 22.7%
The company noted that the initial $10 million tranche, along with $7.5 million from the second SAFE tranche, will be invested by or before May 31, 2025
Lupin to boost complex generics in US, EU; eyes chronic growth in India
Lupin plans to expand complex generics in developed markets and grow its chronic drug portfolio in India, with over 200 product launches and M&A on the radar
 "Lupin to boost complex generics in US, EU; eyes chronic growth in India")
Strong growth seen for Divi's Laboratories, but upside capped by valuations
Divi's posted a 12 per cent growth in revenues over the year-ago quarter. Although revenue growth has moderated after four consecutive quarters of top line growth in the 18-25 per cent range
 "Strong growth seen for Divi's Laboratories, but upside capped by valuations")
Sun Pharma gets USFDA approval for new device to treat skin disease
The company says that the new device is more compact and easier to use than its predecessor
JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%
JB Pharma posts strong FY25 performance with 19.3% profit growth; domestic business up 20%, CDMO segment and Russia drive international gains
 "JB Pharma Q4 results: Profit up 15% to ₹145.6 cr; revenue rises 10%")
Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories
The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term
 "Margin pressures, growth triggers to weigh on Dr Reddy's Laboratories")
US President Donald Trump's drug price slash could sting Indian pharma
Up to 80% US price cuts may squeeze margins, push up innovator drug costs
 "US President Donald Trump's drug price slash could sting Indian pharma")
Trump's 'Make in America' push: Indian drug cos in no rush to make US shift
Pharma industry veteran said that the US wanting to encourage local production is a very natural thing to do
Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr
India branded business grows 8% in Q4FY25 with 4 product launches while Ex-US markets rise 43% and US segment delivers 20% growth during the quarter
 "Alembic Pharma Q4 profit dips 12%, revenue rises 17% to Rs 1,770 cr")